A Double-blind, Randomized, Placebo Controlled Single Site Study to Evaluate the Effects of Evolocumab (AMG 145) Treatment Alone and in Combination with Atorvastatin on Lipoprotein Kinetics

Project Details

StatusFinished
Effective start/end date1/07/1430/06/17

Funding

  • Amgen Australia Pty Ltd: A$520,974.00
  • Amgen Australia Pty Ltd: A$632,376.00
  • Amgen Australia Pty Ltd: A$278,893.00
  • Amgen Australia Pty Ltd: A$157,686.00